Syndromic testing technology allows the identification of infectious agents to determine the most appropriate and rapid treatment
The significant increase in cases of the Ômicron variant in Brazil since the end of December has raised suspicion among the population and caused a rush to hospitalizations. This is because, in addition to the rise in cases of COVID-19 virus, many cities in the country are also experiencing a significant growth in the number of cases of H3N2 (influenza) and other influenza and respiratory syndromes, which can be observed more commonly in winter.
Different diseases have similar symptoms, such as headache, runny nose and fever, because with the immunization of a large part of the population, the new variant of COVID-19 has shown less severe symptoms. As the sense of doubt grew, scenes of emergency care spread to crowded hospitals and laboratories in the early days of the year.
For this reason, an important testing tool has aided clinicians in diagnosis and treatment. Capable of identifying and characterizing a series of pathogens simultaneously, and even determining whether an individual has more than one infectious agent at the same time, QIAstat-Dx has been used in several referral hospitals in the country.
According to the intensive care physician at Hospital das Clínicas, Dr. Daniel Joelson, syndromic testing is essential, especially for professionals working on the front lines of Covid-19. “These tools are very important for us to complete the patient’s diagnosis. If the infection is caused by bacteria, we have already started giving antibiotics. If the patient is infected with the new coronavirus, we provide him with isolation and appropriate treatment.” Syndrome checks facilitate the work of the medical team and reduce side effects. to unnecessary medication.
The proposal of QIAstat-Dx, which is made by QIAGEN – a German multinational specialist in molecular testing technology – is to allow testing of a patient’s respiratory panel, by determining which of the 22 major factors, between bacteria and viruses, are the cause of symptoms, including the coronavirus. The new SARS-Cov-2.
Primarily, QIAGEN’s goal is to assist in the correct diagnosis of diseases that present with similar symptoms. This tool will provide guidance for the most appropriate medical management, by eliminating treatment uncertainty, using the correct medications, and providing a more responsible approach in terms of management and antibiotic resistance,” highlights Paulo Groupe, QIAGEN Vice President, Latin America.
With the goal of clinical diagnosis and active registration in ANVISA, QIAstat-Dx, quickly and without the need for manipulation, directly diagnoses nasopharyngeal swab samples from patients with suspected respiratory infection, and releases the analysis result in up to 1 hour. Its technology has the potential to shorten a patient’s hospital stay, avoid unnecessary hospitalization and identify patients who, depending on contamination, need isolation or other infection control measures.
“Using the tool provides gains for the patient, who receives the correct and effective treatment, recovers and recovers faster. For the health system, avoiding the use of incorrect medications, reducing hospitalization time, reducing costs and increasing the number of vacancies for patients who actually need hospitalization, Paulo Group concludes. , to monitor the most severe cases.
almost QIAGEN
QIAGEN is a German multinational company specializing in molecular diagnostic technology. With more than 5,200 employees in 25 countries, the company offers a portfolio of more than 500 products, including consumables, tool kits, and bioinformatics, that meet diverse global needs, from academic research to routine health applications.
com Attitude.
